RESEARCH

Open Access

Oxycodone versus other opioid analgesics after laparoscopic surgery: a meta-analysis



Yan Li^{1,2,3}, Zhi Dou³, Liqiang Yang³, Qi Wang³, Jiaxiang Ni³ and Jun Ma^{1*}

Abstract

Background: Intravenous opioids are administered for the management of visceral pain after laparoscopic surgery. Whether oxycodone has advantages over other opioids in the treatment of visceral pain is not yet clear.

Methods: In this study, the analgesic efficiency and adverse events of oxycodone and other opioids, including alfentanil, sufentanil, fentanyl, and morphine, in treating post-laparoscopic surgery visceral pain were evaluated. This review was conducted according to the methodological standards described in the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement. The PubMed, Embase, and Cochrane databases were searched in December 2019.

Results: Ten studies were included in this review. The sample size was 695 participants. The results showed that compared with morphine and fentanyl, oxycodone had a more potent analgesic efficacy on the first day after laparoscopic surgery, especially during the first 0.5 h. There was no significant difference in sedation between the two groups. Compared to morphine and fentanyl, oxycodone was more likely to lead to dizziness and drowsiness. Overall, patient satisfaction did not differ significantly between oxycodone and other opioids.

Conclusions: Oxycodone is superior to other analgesics within 24 h after laparoscopic surgery, but its adverse effects should be carefully considered.

Keywords: Meta-analysis, Oxycodone, Laparoscopic surgery, Postoperative visceral pain

Background

Visceral pain is one of the most frequent reasons that patients seek medical attention after laparoscopic surgery [5]. Opioids are the most commonly provided analgesics for postoperative visceral pain, as they can be used prior to the completion of the operation or in the patientcontrolled analgesia (PCA) pump after surgery [1]. However, which kind of opioid is most appropriate is still controversial.

Oxycodone is a semisynthetic drug that is derived from thebaine, an opium alkaloid, and acts as a μ -opioid receptor agonist by affecting the central nervous system.

*Correspondence: drmajun@outlook.com

¹ Center for Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China Full list of author information is available at the end of the article Experiments in rodents suggest that oxycodone also has an effect on the κ -opioid receptor, which is believed to inhibit visceral pain in the visceral nervous system [22]. In animal experiments and clinical observations, oxycodone may occasionally be superior to morphine and fentanyl in the treatment of visceral pain [23]. However, by conducting a meta-analysis, one can detect treatment effects with greater statistical power and estimate these effects with greater precision [24]. To indirectly compare existing evidence on the efficacy of oxycodone and other opioids used in postoperative pain management after laparoscopic surgery, a meta-analysis was performed.

Methods Design

A meta-analysis was performed in this study.



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeco mmons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Data sources

The PubMed, Excerpta Medica (EMBASE), and Cochrane Library databases were searched for trials published from the database inception to December 2019, with no language restrictions. The reference lists of the included studies and relevant reviews were also searched by hand. The search terms included relevant terms and medical subject headings related to oxycodone, laparoscopic surgery, and randomized-controlled trials (RCTs).

The search strategy for each database is presented in Appendix 1.

Inclusion criteria

The types of studies included were RCTs.

The participants in the studies were patients with a clinical diagnosis of visceral pain after laparoscopic surgery.

The types of interventions were oxycodone versus other opioids including alfentanil, sufentanil, fentanyl, and morphine.

The outcomes included pain intensity measured by the visual analogue scale (VAS) or numeric rating scale (NRS), sedation status, adverse events, and patient satisfaction measured by validated scales. We defined pain intensity as the primary endpoint, and sedation and other adverse events as the secondary endpoints.

Study screening

All retrieved studies were imported into Endnote X7 (Thomson ResearchSoft, Stanford, CT). To ensure a high level of confidence between researchers, we conducted a pilot test on literature screening. Two researchers independently reviewed the titles and abstracts of the studies and selected studies that met the eligibility criteria. Then, the full texts of all the studies that met the requirements were reviewed.

Data collected

Using a standardized data sheet in Microsoft Excel 2013 (Microsoft Corp, Redmond, WA, http://www.microsoft. com), two investigators independently extracted data on the study characteristics (e.g., the first author's name, publication year, region where the study was conducted), characteristics of the study subjects (e.g., number of participants, sex distribution), intervention details (e.g., treatment and comparisons), and outcome variables (e.g., adverse events). Any discrepancies observed in the data extracted by the two investigators were resolved by consensus.

Risk of bias of individual studies

The risk of bias of the included RCTs was assessed according to the Cochrane Handbook, version 5.1.0 [8], and the

aspects assessed included the method of random sequence generation (selection bias), allocation concealment (selection bias), blinding (performance bias and detection bias), incomplete outcome data (detection bias), selective reporting (detection bias), and other bias. We considered the risk of bias to be low, high, or unclear. The risk of bias assessment was completed by two independent reviewers, and conflicts were resolved by a third reviewer.

Meta-analysis

A meta-analysis was conducted using RevMan 5.3 software. The combined risk ratio (RR) and the 95% confidence interval (CI) were calculated for the dichotomous data. The heterogeneity of the therapeutic effects in the trials was assessed by χ^2 and I^2 . If there was no statistical heterogeneity (the *p* value was ≥ 0.1 and $I^2 \leq 50\%$), the Mantel–Haenszel fixed-effects model was used for the meta-analysis [8]. Otherwise, we explored the potential causes of heterogeneity through subgroup analysis and meta-regression. If no clinical heterogeneity was detected, the meta-analysis was performed using the Mantel–Haenszel random-effects model.

Results

Literature selection


The search strategy and selection process for the published articles are described in Fig. 1. A total of 145 studies were identified in the search. Of them, 122 articles were excluded after the titles and abstracts were screened. The remaining 23 studies concerning oxycodone for visceral pain after laparoscopic surgery were assessed. Among them, 15 studies were excluded, because they were non-randomized-controlled trials (n=1), the patients did not meet our inclusion criteria (n=9), and the outcomes reported did not meet our inclusion criteria (n=2). A total of nine studies [3, 4, 7, 9,10, 12-15, 20] met our inclusion criteria.

Characteristics of the included studies

A total of 695 participants (including 347 oxycodone subjects and 348 controls) met the inclusion criteria and were included in the data analysis; the study design and location, characteristics of the patients (diagnosis, duration of surgery, duration of anaesthesia, American Society of Anesthesiologists (ASA) physical status I/II), and details about the interventions and measured outcomes are presented in Table 1.

Risk of bias results for the individual studies

The risk of bias results for the included studies determined according to the Cochrane risk of bias tool are provided in Fig. 2. Of the nine studies that were included,




six studies were rated as having a low risk of bias regarding randomization, as they used computer-generated random number sequences. Three studies [9, 10, 20] did not describe the method of randomization. Most studies stated that allocation concealment was conducted: however, four studies [9, 10, 14, 20] did not report this information. Fewer than half of the included studies stated that the participants and personnel were blinded. The other five studies [9, 10, 14, 15, 20] did not report this information. For blinding of the outcome assessor, one study [13] stated that some of the outcome assessors knew the group assignments during treatment, so it was rated as having a high risk of bias in this domain. One study [15] did not report data for some measured outcomes, including nausea, vomiting, or itching; therefore, it was rated as having a high risk of selective reporting bias.

Meta-analysis

Pain intensity

Nine studies [3, 4, 9, 10, 12–15, 20] measured pain intensity by the VAS or NRS. However, data from only four of them [9, 12, 14, 15] were included in the meta-analysis. The results showed that oxycodone significantly reduced pain intensity compared with other opioids (fentanyl, alfentanil, or morphine) at 30 min (2 RCTs, N = 218, MD - 11.9, 95% CI -16.16 to - 7.63), 4 h (3 RCTs, N = 290, MD - 4.73, 95% CI - 8.9 to - 0.57), and 24 h postoperatively (2 RCTs, N=208, MD - 3.00, 95% CI - 4.02 to - 1.98) but not at 48 h postoperatively (2 RCTs, N = 208, MD - 0.62, 95% CI - 3.00 to 1.76) (Fig. 3). The data of the other five studies were not included in the meta-analysis, because the data were skewed. These results are consistent with those reported by Kim et al. [10], Choi et al. [3], and Park et al. [20] which concluded that oxycodone and



Oxycodone Other opioids						Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.1.1 0.5h									_
Kim 2017	34	3	64	47	2.5	63	79.6%	-13.00 [-13.96, -12.04]	
Lenz 2009	45	21.2147	46	52.6	18.6397	45	20.4%	-7.60 [-15.80, 0.60]	
Subtotal (95% CI)			110			108	100.0%	-11.90 [-16.16, -7.63]	◆
Heterogeneity: Tau ² =	5.71; Cł	ni² = 1.64, 1	df = 1 (P = 0.20	l); I ^z = 39%				
Test for overall effect: .	Z = 5.47	(P < 0.000	001)						
1.1.2 4h									
Hwang 2014	33	13	41	37	17	40	23.3%	-4.00 [-10.60, 2.60]	
Kim 2017	32	3	64	39	3	63	54.3%	-7.00 [-8.04, -5.96]	
Kwon 2016	36	16.5	41	36	15	41	22.4%	0.00 [-6.83, 6.83]	
Subtotal (95% CI)			146			144	100.0%	-4.73 [-8.90, -0.57]	•
Heterogeneity: Tau ² = Test for overall effect: .				P = 0.10	i), i= 07%	,			
1.1.3 24h									
Hwang 2014	23	7	41	26	13	40	5.0%		
Kim 2017	17	3	64	20	3	63		-3.00 [-4.04, -1.96]	.
Subtotal (95% CI)			105			103	100.0%	-3.00 [-4.02, -1.98]	•
Heterogeneity: Tau ² = Test for overall effect: .				P = 1.00	l); I² = 0%				
1.1.4 48h									
Hwang 2014	20	9	41	23	12	40	20.6%	-3.00 [-7.63, 1.63]	
Kim 2017	14	3	64	14	3	63		0.00 [-1.04, 1.04]	
Subtotal (95% CI)			105			103	100.0%	-0.62 [-3.00, 1.76]	•
Heterogeneity: Tau ² = Test for overall effect: :				P = 0.22	?); I² = 35%				
								_	
									-20 -10 0 10 20 Favours [Oxycodone] Favours [Fentanyl]
Test for subaroup diffe	erences	: Chi² = 21	.16. df	= 3 (P <	0.0001). P	² = 85.8	3%		ravours (oxycodonej ravours (remanyi)

fentanyl have equal effectiveness in relieving postoperative pain. Choi et al. [4] found that the pain intensity in the oxycodone group was significantly lower than that in the fentanyl group at 0.5 h postoperatively, but this effect did not last longer than 0.5 h. Koch 2008 [13] stated that the intensity of deep abdominal pain was significantly lower in the oxycodone group upon arrival, after 30, 60, and 90 min, and upon discharge from the PACU.

Sedation

Four studies [4, 9, 13, 15] reported this outcome. Choi et al. [4] and Koch et al. [13] used the following methods to assess sedation: "S, asleep, easily aroused; 1, awake and alert; 2, occasionally drowsy, easily aroused; 3, frequently drowsy, falls asleep during conversation; 4, somnolent, minimal or no response to stimulation". The meta-analysis showed that there were no differences between oxycodone and fentanyl, as the sedation scores were 2 (2RCTs,

N=127, RR 2.06, 95% CI 0.56–7.60, Fig. 4). Both studies reported that no patients had a sedation score of 3 or 4. Two studies used different measurements to evaluate the sedation effects. Hwang et al. [9] also concluded that the sedation level was similar between the oxycodone and fentanyl groups. However, Lenz et al. [15] found a different result: the sedation level was significantly lower in the oxycodone group than in the morphine group (P=0.006).

Adverse events

All studies reported adverse events. Oxycodone may induce a higher risk of dizziness (6 RCTs, N=455, RR 2.31, 95% CI 1.64–3.27), drowsiness (1 RCT, N=127, RR 7.88, 95% CI 1.89–32.85), and nausea (7 RCT, N=549, RR 1.79, 95% CI 1.01–3.18). There were no differences between groups in the risk of headache, pruritus, respiratory depression, or vomiting (Fig. 5).

Patient satisfaction

Patient satisfaction was classified into four levels: very satisfied, satisfied, neutral, and dissatisfied. A meta-analysis was performed to assess the number of patients who were satisfied or very satisfied in the two groups. The results from four studies [9, 10, 12, 14] showed that there were no significant differences between oxycodone and other opioids in this outcome (4 RCTs, N= 350, RR 0.88, 95% CI 0.66–1.17, Fig. 6).

Discussion

Summary of findings

A total of 9 studies, including 695 patients, were included in this meta-analysis to compare the analgesic effect of oxycodone and other opioids, including fentanyl, morphine, sufentanil, and alfentanil. Most of the included studies reported the efficacy of oxycodone and indicated that it was superior to other analgesics in treating visceral pain within 24 h after laparoscopic surgery [9, 10, 12, 14, 15]. However, there was no significant difference in the pain scores between the oxycodone group and other opioid groups at 48 h after surgery. There does not appear to be a clear consensus regarding the findings on the sedation level, adverse events, or patient satisfaction. However, this finding suggests that oxycodone may induce a higher risk of dizziness and drowsiness than do other opioids. We also found no significant differences in patient satisfaction between these other opioids and oxycodone.

Quality of the evidence


The quality of the evidence was fair. Most studies were rated as having a low risk of bias regarding randomization, allocation concealment, blinding, the attrition rate, and selective reporting. Only two studies (Koch, Lenz) were rated as having poor quality, owing to issues of imprecision (small sample size and a sparse number of events observed) and risk of bias (unclear reporting of allocation concealment and blinding).

Analgesic efficacy

Postoperative pain after laparoscopic surgery consists of three components: incisional pain (somatic), deep abdominal pain (visceral), and inflammatory pain after carbon dioxide is absorbed by the peritoneum (also referred to as visceral pain) [13]. This study used the ideal clinical design to test the effectiveness of visceral pain treatments, and the somatic pain component was minimized.


Four of the included studies showed that oxycodone is more potent in the treatment of visceral pain than is morphine or fentanyl during the first 0.5 h after surgery. In these studies, the intensity of analgesic drugs peaked at this time point. Fentanyl has a rapid onset of action (5–7 min), which is much faster than that of oxycodone (10–15 min) [11]. Although morphine is considered to be a slower acting drug, it was given to patients 10–15 min before the end of surgery in Lens's study [15]. Therefore, the onset time cannot be used to explain the difference in their initial pain relief.

The analgesic effects of oxycodone may be explained by a specific mechanism. Several recent studies have



```
(See figure on next page.)
Fig. 5 Meta-analysis of adverse events. Cl confidence interval
```

Study or Subgroup	Oxycodone	Other of	shioid		Risk Ratio	Risk Ratio
	Events Tot			Weight	M-H. Random. 95% C	
1.1.1 Dizziness	Events 10	a Events	Total	weight	m-n, Random, 95% C	
	0	• •	00		Not ortinat to	
Choi 2015		8 0	26	1 00/	Not estimable	
Choi 2018		0 1	30	1.2%	0.33 [0.01, 7.87]	
Kim 2015		0 6	30	13.9%	1.33 [0.53, 3.38]	
Kim 2017		4 16	63	57.5%	2.65 [1.68, 4.18]	
Kwon 2016		1 6	41	16.0%	2.17 [0.91, 5.15]	
Park 2015		7 4	35	11.5%	3.07 [1.11, 8.53]	
Subtotal (95% CI)	23	0	225	100.0%	2.31 [1.64, 3.27]	
Total events	77	33				
Heterogeneity: Tau ² =	0.00; Chi ² = 3.4	5, df = 4 (P	= 0.49);	$^{2} = 0\%$		
Test for overall effect:						
1.1.2 Drowsiness						_
Kim 2017	16 0	4 2	63	100.0%	7.88 [1.89, 32.85]	
Subtotal (95% CI)		4		100.0%	7.88 [1.89, 32.85]	
Total events	16	2				
Heterogeneity: Not ap		-				
Test for overall effect:		005)				
rest for overall effect.	Z = 2.03 (P = 0	005)				
442 Handasha						
1.1.3 Headache	-					
Hwang 2014		1 1	40	7.3%	1.95 [0.18, 20.68]	
Kim 2015		0 4	30	24.3%	1.00 [0.28, 3.63]	
Kim 2017		4 9	63	51.5%	0.88 [0.36, 2.12]	
Kwon 2016	2 4	1 1	41	7.3%	2.00 [0.19, 21.21]	
Park 2015		7 1	35	9.7%	6.62 [0.86, 51.11]	•
Subtotal (95% CI)	21			100.0%	1.24 [0.66, 2.34]	
Total events	23	16				
Heterogeneity: Tau ² =			= 0 44).	$^{2} = 0%$		
			0.44),	- 0 /0		
Test for overall effect:	2 - 0.00 (P = 0	51)				
1 1 A Drugitio						
1.1.4 Pruritis					0.00 10.01 0.00	
Hwang 2014		1 3	40	14.5%	0.33 [0.04, 3.00]	
Kim 2015		0 3	30	35.0%	1.33 [0.33, 5.45]	
Kim 2017		4 3	63	43.3%	2.95 [0.84, 10.41]	
Kwon 2016		1 0	41	7.2%	3.00 [0.13, 71.56]	
Subtotal (95% CI)	17	6	174	100.0%	1.62 [0.69, 3.82]	
Total events	15	9				
Test for overall effect:		27)				
1.1.5 Respiratory dep		0 0	00		N	
Choi 2018		0 0	30		Not estimable	
Hwang 2014		1 0	40		Not estimable	
Kim 2015		0 0	30		Not estimable	
Kim 2017		4 0	63		Not estimable	
Kwon 2016		1 1		100.0%	1.00 [0.06, 15.45]	
Subtotal (95% CI)	20		204	100.0%	1.00 [0.06, 15.45]	
Total events	1	1				
Heterogeneity: Not ap	oliooblo					
rictorogeneity. Hot up	plicable					
		00)				
		00)				
Test for overall effect:		00)				
Test for overall effect: 1.1.6 Nausea	Z = 0.00 (P = 1		26	3.0%	2.79 [0 12 65 66]	
Test for overall effect: 1.1.6 Nausea Choi 2015	Z = 0.00 (P = 1	8 0	26	3.0%	2.79 [0.12, 65.66]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014	Z = 0.00 (P = 1 1 2 22 4	8 0 1 14	40	21.9%	1.53 [0.92, 2.55]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015	Z = 0.00 (P = 1 1 22 12 3	8 0 1 14 0 4	40 30	21.9% 14.6%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017	Z = 0.00 (P = 1 1 2 12 3 12 3 18 6	8 0 1 14 0 4 4 2	40 30 63	21.9% 14.6% 10.2%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008	Z = 0.00 (P = 1 1 22 12 3 18 6 10 5	8 0 1 14 0 4 4 2 6 7	40 30 63 37	21.9% 14.6% 10.2% 16.8%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016	Z = 0.00 (P = 1 1 22 12 3 18 6 10 3 8 4	8 0 1 14 0 4 4 2 6 7 1 14	40 30 63 37 41	21.9% 14.6% 10.2% 16.8% 18.2%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015	Z = 0.00 (P = 1 1 22 12 3 18 6 10 3 8 4 11 3	8 0 1 14 0 4 4 2 6 7 1 14 7 5	40 30 63 37 41 35	21.9% 14.6% 10.2% 16.8% 18.2% 15.4%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016	Z = 0.00 (P = 1 1 22 12 3 18 6 10 3 8 4	8 0 1 14 0 4 4 2 6 7 1 14 7 5	40 30 63 37 41 35	21.9% 14.6% 10.2% 16.8% 18.2%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI)	Z = 0.00 (P = 1 1 22 12 3 18 6 10 3 8 4 11 3	8 0 1 14 0 4 4 2 6 7 1 14 7 5	40 30 63 37 41 35	21.9% 14.6% 10.2% 16.8% 18.2% 15.4%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events	Z = 0.00 (P = 1 1 22 12 3 18 4 10 3 8 4 11 2 8 4 21 82	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46	40 30 63 37 41 35 272	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015	Z = 0.00 (P = 1 1 22 12 3 18 4 10 3 8 4 11 3 21 0.33; Chi ² = 15	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F	40 30 63 37 41 35 272	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect:	Z = 0.00 (P = 1 1 22 12 3 18 4 10 3 8 4 11 3 21 0.33; Chi ² = 15	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F	40 30 63 37 41 35 272	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting	Z = 0.00 (P = 1 1 2 22 4 12 5 18 4 10 5 8 4 11 2 27 82 0.33; Chi ² = 15 Z = 1.98 (P = 0	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05)	40 30 63 37 41 35 272 9 = 0.02);	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015	Z = 0.00 (P = 1 1 2 22 4 12 5 18 6 10 5 8 4 11 5 21 82 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0	40 30 63 37 41 35 272 9 = 0.02); 26	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014	Z = 0.00 (P = 1 1 2 12 1 18 1 10 2 11 2 18 2 11 2 21 8 2 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 4	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0	40 30 63 37 41 35 272 9 = 0.02); 26 40	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable Not estimable	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% Cl) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015	Z = 0.00 (P = 1 1 : 22 4 12 : 18 0 10 : 18 0 10 : 21 82 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 : 3 : 3 :	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1	40 30 63 37 41 35 272 9 = 0.02); 26 40 30	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable Not estimable 3.00 [0.33, 27.23]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017	Z = 0.00 (P = 1 1 2 22 4 12 5 18 6 10 5 8 4 11 2 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 3 2 2 6	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1 4 3	40 30 63 37 41 35 272 9 = 0.02); 26 40 30 63	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0% 1 ² = 61%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017	Z = 0.00 (P = 1 1 2 22 4 12 5 18 6 10 5 22 4 12 5 22 4 12 5 22 4 12 5 22 4 12 5 21 22 5 21 21 21 21 21 21 21 21 21 21	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1	40 30 63 37 41 35 272 9 = 0.02); 26 40 30	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting	Z = 0.00 (P = 1 1 2 22 4 12 5 18 6 10 5 21 82 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 4 2 6 5 5	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1 4 3	40 30 63 37 41 35 272 9 = 0.02); 26 40 30 63	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0% 1 ² = 61%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2017 Kim 2017 Kim 2017	Z = 0.00 (P = 1) 1 2 22 4 12 5 18 0 10 5 8 2 11 5 27 82 0.33; Chi ² = 15 Z = 1.98 (P = 0) 0 2 0 4 3 5 2 0 0 4 5 5 0 4 0 4 0 4 0 4 0 4 0 4 0 4 0 4	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1 4 3 6 2	40 30 63 37 41 35 272 9 = 0.02); 26 40 30 63 37	21.9% 14.6% 10.2% 16.8% 15.4% 100.0% r ² = 61%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40] 0.20 [0.01, 4.04]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015	Z = 0.00 (P = 1) 1 2 22 4 12 5 18 0 10 5 8 2 11 5 27 82 0.33; Chi ² = 15 Z = 1.98 (P = 0) 0 2 0 4 3 5 2 0 0 4 5 5 0 4 0 4 0 4 0 4 0 4 0 4 0 4 0 4	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1 4 3 6 2 1 2 7 2	40 30 63 37 41 35 272 26 40 30 63 37 41 35	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0% 1 ² = 61% 14.9% 23.5% 29.3% 8.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI)	Z = 0.00 (P = 1) 1 22 12 1 18 4 10 2 8 4 11 2 18 5 10 2 10 2	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1 4 3 6 2 1 2 7 2 7	40 30 63 37 41 35 272 26 40 30 63 37 41 35	21.9% 14.6% 10.2% 16.8% 18.2% 15.4% 100.0% ² = 61% 23.5% 29.3% 29.3% 24.3%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40] 0.20 [0.01, 4.04] 1.42 [0.25, 7.99]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events	Z = 0.00 (P = 1 1 22 12 3 18 4 10 3 8 4 11 3 21 82 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 4 3 3 2 4 0 4 3 3 2 1 13	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 0 1 4 3 6 2 1 2 7 2 7 10	40 30 63 37 41 35 272 26 40 30 63 37 41 35 272 272	21.9% 14.6% 10.2% 16.8% 15.4% 100.0% 1 ² = 61% 23.5% 29.3% 8.0% 24.3% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40] 0.20 [0.01, 4.04] 1.42 [0.25, 7.99]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	Z = 0.00 (P = 1 1 22 12 3 18 0 10 3 18 0 10 3 18 0 10 3 21 2 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 4 3 3 2 0 0 4 3 3 2 1 0 4 3 4 1 4 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 1 0 1 4 3 6 6 2 1 2 7 2 1 2 7 1 2 7 1 0 6 4 4 6 (F) 8 0 1 0 1 4 6 (F) 8 0 1 0 1 4 4 3 6 6 7 1 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 1 4 3 0 6 2 1 2 7 10 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 0 0 1 2 7 10 1 0 0 0 1 1 4 3 6 6 7 1 7 10 1 0 0 0 1 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 1 0 1 0 1 0	40 30 63 37 41 35 272 26 40 30 63 37 41 35 272 272	21.9% 14.6% 10.2% 16.8% 15.4% 100.0% 1 ² = 61% 23.5% 29.3% 8.0% 24.3% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40] 0.20 [0.01, 4.04] 1.42 [0.25, 7.99]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events	Z = 0.00 (P = 1 1 22 12 3 18 0 10 3 18 0 10 3 18 0 10 3 21 2 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 2 0 3 2 0 0 2 0 2 13 0.00; Chi ² = 3.3	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 1 0 1 4 3 6 6 2 1 2 7 2 1 2 7 1 2 7 1 0 6 4 4 6 (F) 8 0 1 0 1 4 6 (F) 8 0 1 0 1 4 4 3 6 6 7 1 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 1 4 3 0 6 2 1 2 7 10 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 0 0 1 2 7 10 1 0 0 0 1 1 4 3 6 6 7 1 7 10 1 0 0 0 1 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 1 0 1 0 1 0	40 30 63 37 41 35 272 26 40 30 63 37 41 35 272 272	21.9% 14.6% 10.2% 16.8% 15.4% 100.0% 1 ² = 61% 23.5% 29.3% 8.0% 24.3% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40] 0.20 [0.01, 4.04] 1.42 [0.25, 7.99]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	Z = 0.00 (P = 1 1 22 12 3 18 0 10 3 18 0 10 3 18 0 10 3 21 2 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 2 0 3 2 0 0 2 0 2 13 0.00; Chi ² = 3.3	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 1 0 1 4 3 6 6 2 1 2 7 2 1 2 7 1 2 7 1 0 6 4 4 6 (F) 8 0 1 0 1 4 6 (F) 8 0 1 0 1 4 4 3 6 6 7 1 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 1 4 3 0 6 2 1 2 7 10 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 0 0 1 2 7 10 1 0 0 0 1 1 4 3 6 6 7 1 7 10 1 0 0 0 1 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 1 0 1 0 1 0	40 30 63 37 41 35 272 26 40 30 63 37 41 35 272 272	21.9% 14.6% 10.2% 16.8% 15.4% 100.0% 1 ² = 61% 23.5% 29.3% 8.0% 24.3% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40] 0.20 [0.01, 4.04] 1.42 [0.25, 7.99]	
Test for overall effect: 1.1.6 Nausea Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² = Test for overall effect: 1.1.7 Vomitting Choi 2015 Hwang 2014 Kim 2015 Kim 2017 Koch 2008 Kwon 2016 Park 2015 Subtotal (95% CI) Total events Heterogeneity: Tau ² =	Z = 0.00 (P = 1 1 22 12 3 18 0 10 3 18 0 10 3 18 0 10 3 21 2 0.33; Chi ² = 15 Z = 1.98 (P = 0 0 2 0 2 0 3 2 0 0 2 0 2 13 0.00; Chi ² = 3.3	8 0 1 14 0 4 4 2 6 7 1 14 7 5 7 46 23, df = 6 (F 05) 8 0 1 0 1 0 1 4 3 6 6 2 1 2 7 2 1 2 7 1 2 7 1 0 6 4 4 6 (F) 8 0 1 0 1 4 6 (F) 8 0 1 0 1 4 4 3 6 6 7 1 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 1 4 3 0 6 2 1 2 7 10 1 4 6 (F) 8 0 1 0 1 4 3 0 6 2 1 0 1 0 0 0 1 2 7 10 1 0 0 0 1 1 4 3 6 6 7 1 7 10 1 0 0 0 1 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 0 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 6 2 7 10 1 0 1 0 1 0 1 0 1 0 1 0 1 0	40 30 63 37 41 35 272 26 40 30 63 37 41 35 272 272	21.9% 14.6% 10.2% 16.8% 15.4% 100.0% 1 ² = 61% 23.5% 29.3% 8.0% 24.3% 100.0%	1.53 [0.92, 2.55] 3.00 [1.09, 8.25] 8.86 [2.14, 36.61] 1.47 [0.63, 3.43] 0.57 [0.27, 1.21] 2.08 [0.80, 5.39] 1.79 [1.01, 3.18] Not estimable 3.00 [0.33, 27.23] 0.66 [0.11, 3.80] 2.57 [0.53, 12.40] 0.20 [0.01, 4.04] 1.42 [0.25, 7.99]	



suggested that oxycodone attenuates visceral pain better than do other opioids [16, 18, 23]. Oxycodone has a proposed effect on the κ -opioid receptor, which reflects a different pharmacological profile from those of other opioids. κ -opioid receptors on peripheral nerves in the gut have been suggested as important components in anti-nociception in the visceral pain system [25]. The analgesic effect of oxycodone correlates with the plasma concentration, indicating an effect in the periphery that is perhaps mediated via κ -receptors [26].

This meta-analysis also showed that at 4 h and 24 h, the analgesic effect of oxycodone is superior to that of other opioids, regardless of whether a single dose was administered at the end of the surgery or the dose was administered using a PCA pump. These findings indicate that oxycodone is more potent than are other opioids in the treatment of postoperative visceral pain with the equivalent dose. However, the analgesic advantage of oxycodone did not last for more than 48 h after surgery, regardless of whether a single dose [9] or a dose via a PCA pump [12] was administered. A possible explanation is that the pain intensity 48 h after such a minor surgery may be too low to yield a significant difference in pain scores [6]. Moreover, it should be noted that because the included studies generally have low pain level, when oxycodone is used for postoperative analgesia in other higher level pain surgeries, its analgetic effect on visceral pain is not yet known, and further research is needed.

Safety evaluation

Sedation is an important indicator for evaluating the safety of a drug for postoperative analgesia [17]. Lenz et al. found that the sedation level was significantly lower in the oxycodone group than in the morphine group [15]. The meta-analysis showed that the oxycodone groups had similar sedation levels to the morphine and fentanyl groups, and there was no incidence of excessive sedation or respiratory depression in any of the groups.

According to previous studies, the adverse effects associated with opioid use include constipation, nausea, vomiting, drowsiness, dizziness, and pruritus [2, 19]. The specific incidence of the adverse effects varies greatly, depending on the dosage. A higher incidence of dizziness and nausea was reported with oxycodone than with fentanyl and morphine in our study. The precise mechanism of opioid-induced dizziness is unknown. Vestibular sensitivity caused by opioids activating µ receptors in the vestibular epithelium may be involved [11]. Nevertheless, the potential causes of the varied incidence of dizziness still need to be explored further. Among previous studies, the reported incidence of side effects differed widely, probably because most studies were designed to have a statistical power sufficient for investigating analgesic efficacy rather than differences in side effects. In addition, since laparoscopic abdominal surgery often affects intestinal function, it is also important to understand the difference between intestinal paralysis and constipation. However, the included studies did not report these two results.

Strength and limitations

This meta-analysis has several strengths. First, our search strategy was developed by an information specialist to avoid missing any relevant trials. Second, two reviewers screened and extracted the data to reduce system error in the fabrication process. Similar to other studies, our meta-analysis also had some limitations: there were only a small number of clinical trials available, which contributed a relatively small sample size for the meta-analysis. Second, age and gender may also alter opioid pharmacokinetics and influence pain. The mean age was relatively high in the present patient population (40-69) and the number of female patients accounted for a large proportion in three included studies [3, 13, 14]. Third, two studies had excluded patients undergoing chronic pain medications [9, 14], but for other studies, if patients have chronic pain disease before surgery, or have long-term regular use of analgesics, anticonvulsants, and antidepressants, it may have an impact on the results of the study. Without a washout period, these drugs may have a synergistic effect with opioids, resulting in lower pain scores. Fourth, publication bias may have resulted in the overestimation of some outcomes, as positive results are more likely to be published than are negative ones [21].

Conclusion

Choosing the best opioid for postoperative visceral pain treatment is complicated, as no universally accepted "gold standard" exists. The results of this meta-analysis suggest that oxycodone is superior to other analgesics within 24 h after laparoscopic surgery. However, in some cases, even when it is effective, its incidence of adverse reactions, especially dizziness, is high. Clinicians must choose appropriate opioids based on their clinical judgement and adjust the dose as needed. To obtain the best clinical evidence, it is necessary to perform more indepth research in this field.

Abbreviations

PCA: Patient-controlled analgesia; RCTs: Randomized-controlled trials; VAS: Visual analogue scale; NRS: Numeric rating scale; RR: Risk ratio; CI: Confidence interval; ASA: American Society of Anesthesiologists.

Acknowledgements

Not applicable.

Authors' contributions

YL and ZD are the co-first authors who contributed equally to the statistical analysis and drafted the manuscript. LY helped design the study and draft

Appendix 1

EMBASE.COM

the manuscript. QW and JN helped design the study and collect data. JM conceived of the study and helped draft the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the China Postdoctoral Science Foundation [2019M650769], Beijing Postdoctoral Research Foundation [2018-ZZ-108,2018], and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX201810].

Availability of data and materials

The datasets used and analysed for the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent for publication was obtained from all participants.

Competing interests

No conflicts of interest exist regarding the submission of this manuscript.

Author details

 ¹ Center for Anesthesiology, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China.
 ² Department of Anesthesiology, The People's Hospital of Jizhou District, Tianjin 301900, Tianjin, China.
 ³ Department of Pain Management, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

LIVIDI		
#11	#8 OR #10	73
#10	#3 AND #6 AND #9	2
#9	(((('meta analysis'/exp OR 'meta analysis (topic)'/exp OR 'systematic review/exp OR 'systematic review (topic)'/exp OR meta) AND analysis:ti,ab OR meta) AND analyses:ti,ab OR 'meta analysis':ti,ab OR 'meta analyses':ti,ab OR systematic) AND review:ti,ab OR systematic) AND reviews:ti,ab OR metaanalysis:ti,ab OR metaanalyses:ti,ab	40,965
#8	#3 AND #6 AND #7	73
#7	'multicenter study (topic)'/exp OR 'phase 2 clinical trial (topic)'/exp OR 'phase 3 clinical trial (topic)'/exp OR 'phase 4 clinical trial (topic)'/exp OR 'controlled clinical trial (topic)'/exp OR 'randomized controlled trial (topic)'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR random*:ab,ti OR blind*:ab,ti OR singleblind*:ab,ti OR doubleblind*:ab,ti OR trebleblind*:ab,ti OR tripleblind*:ab,ti	1,498,590
#6	#4 OR #5	139,593
#5	laparoscopy:ab,ti OR laparoscopies:ab,ti OR celioscopy:ab,ti OR celioscopies:ab,ti OR peritoneoscopy:ab,ti OR peritoneoscopies:ab,ti OR 'laparoscopic surgical procedures':ab,ti OR 'laparoscopic surgical procedure':ab,ti OR 'laparoscopic surgery':ab,ti OR 'laparoscopic surgeries':ab,ti OR 'laparoscopic assisted surgery':ab,ti OR 'laparoscopic assisted surgeries':ab,ti OR videolaparoscopy:ab,ti OR videolaparoscopies:ab,ti	64,101
#4	'laparoscopy'/exp OR 'hand assisted laparoscopy'/exp OR 'laparoendoscopic single site surgery'/exp OR 'laparoscopic cholecystectomy'/exp OR 'laparoscopic surgery'/exp	131,003
#3	#1 OR #2	13,813
#2	((dihydrohydroxycodeinone;ab,ti OR oxycodeinon;ab,ti OR theocodin;ab,ti OR oxycodone;ab,ti OR dihydrohydroxydodeinone;ab,ti OR dihydrone;ab,ti OR dinarkon;ab,ti OR endone;ab,ti OR eubine;ab,ti OR eucodal;ab,ti OR narcosin;ab,ti OR oxicontin;ab,ti OR oxicontin;ab,ti OR oxiconum;ab,ti OR oxiconum;ab,ti OR oxiconum;ab,ti OR oxylor;ab,ti OR oxylor;	286
		40 700

#1 'oxycodone'/exp

PubMed

13,789

<u>#16</u>	Add	Search #13 OR #15	<u>37</u>
<u>#15</u>	Add	Search #6 AND #9 AND #14	2
<u>#14</u>	<u>Add</u>	Search "Meta-Analysis" [Publication Type] OR "Meta-Analysis as Topic"[Mesh] OR meta analysis[Title/Abstract] OR meta analyses[Title/Abstract] OR meta-analysis[Title/Abstract] OR meta- analyses[Title/Abstract] OR systematic review[Title/Abstract] OR systematic reviews[Title/Abstract] OR metaanalysis[Title/Abstract] OR metaanalyses[Title/Abstract]	<u>199010</u>
<u>#13</u>	Add	Search #6 AND #9 AND #12	<u>36</u>
<u>#12</u>	Add	Search #10 OR #11	<u>1131090</u>
<u>#11</u>	<u>Add</u>	Search random*[Title/Abstract] OR blind*[Title/Abstract] OR singleblind*[Title/Abstract] OR doubleblind*[Title/Abstract] OR trebleblind*[Title/Abstract] OR trebleblind*[Title/Abstract]	<u>1043964</u>
<u>#10</u>	<u>Add</u>	Search "Clinical Trials, Phase II as Topic"[Mesh] OR "Clinical Trials, Phase III as Topic"[Mesh] OR "Clinical Trials, Phase IV as Topic"[Mesh] OR "Controlled Clinical Trials as Topic"[Mesh] OR "Randomized Controlled Trials as Topic"[Mesh] OR "Intention to Treat Analysis"[Mesh] OR "Pragmatic Clinical Trials as Topic"[Mesh] OR "Clinical Trials, Phase II"[Publication Type] OR "Clinical Trials, Phase III"[Publication Type] OR "Clinical Trials, Phase IV"[Publication Type] OR "Controlled Clinical Trials"[Publication Type] OR "Randomized Controlled Trials"[Publication Type] OR "Pragmatic Clinical Trials as Topic"[Publication Type] OR "Randomized Controlled Trials"[Publication Type] OR "Pragmatic Clinical Trials as Topic"[Publication Type] OR "Single-Blind Method"[Mesh] OR "Double-Blind Method"[Mesh]	<u>281342</u>
<u>#9</u>	Add	Search #7 OR #8	<u>98916</u>
<u>#8</u>	<u>Add</u>	Search Laparoscopy [Title/Abstract] OR Laparoscopies [Title/Abstract] OR Celioscopy [Title/Abstract] OR Celioscopies [Title/Abstract] OR Peritoneoscopy [Title/Abstract] OR Peritoneoscopies [Title/Abstract] OR Laparoscopic Surgical Procedures [Title/Abstract] OR Laparoscopic Surgical Procedure [Title/Abstract] OR Laparoscopic Surgery [Title/Abstract] OR Laparoscopic Surgeries [Title/Abstract] OR Laparoscopic Assisted Surgery [Title/Abstract] OR Laparoscopic Assisted Surgeries [Title/Abstract] OR videolaparoscopy [Title/Abstract] OR videolaparoscopies [Title/Abstract] OR videolaparoscopy [Title/Abstract] OR videolaparoscopies	<u>46053</u>
<u>#7</u>	Add	Search "Laparoscopy"[Mesh] OR "Cholecystectomy, Laparoscopic"[Mesh] OR "Hand-Assisted Laparoscopy"[Mesh]	<u>83164</u>
<u>#6</u>	Add	Search #4 OR #5	75644

<u>#5</u>	Add	Search Dihydrone[Title/Abstract] OR Dinarkon[Title/Abstract] OR Oxycone[Title/Abstract] OR Dihydrohydroxycodeinone[Title/Abstract] OR Oxycodeinon[Title/Abstract] OR Oxiconum[Title/Abstract] OR Theocodin[Title/Abstract] OR Oxycodnl[Title/Abstract] OR Oxycodone[Title/Abstract] OR Pancodine[Title/Abstract] OR Coxycodein[Title/Abstract] OR dihydrohydroxydodeinone[Title/Abstract] OR dihydrone[Title/Abstract] OR dinarkon[Title/Abstract] OR eucodale[Title/Abstract] OR eubine[Title/Abstract] OR eudoal[Title/Abstract] OR eucodale[Title/Abstract] OR eucodalum[Title/Abstract] OR eudoal[Title/Abstract] OR eucodale[Title/Abstract] OR eukodal[Title/Abstract] OR eumorphal[Title/Abstract] OR eurodamine[Title/Abstract] OR eutagen[Title/Abstract] OR hydrocodal[Title/Abstract] OR eurodamine[Title/Abstract] OR ludonal[Title/Abstract] OR movy[Title/Abstract] OR hydroxycodeinoma[Title/Abstract] OR ludonal[Title/Abstract] OR movy[Title/Abstract] OR medicodal[Title/Abstract] OR narcobasina[Title/Abstract] OR narcobasine[Title/Abstract] OR narcosin[Title/Abstract] OR narcobasina[Title/Abstract] OR narcobasine[Title/Abstract] OR ossicodone[Title/Abstract] OR oxanest[Title/Abstract] OR oxaydo[Title/Abstract] OR oxecta[Title/Abstract] OR oxicone[Title/Abstract] OR oxyaydo[Title/Abstract] OR oxycod[Title/Abstract] OR oxicone[Title/Abstract] OR oxy ri[Title/Abstract] OR oxycod[Title/Abstract] OR oxycodeinonhydrochloride[Title/Abstract] OR oxycodnhydrochlorid[Title/Abstract] OR oxycody[Title/Abstract] OR oxycodnhydrochlorid[Title/Abstract] OR oxycody[Title/Abstract] OR oxycodnhydrochlorid[Title/Abstract] OR oxycontin [Title/Abstract] OR oxyidse[Title/Abstract] OR oxycontin cr[Title/Abstract] OR oxyidse[Title/Abstract] OR oxycontin cr[Title/Abstract] OR oxycodnn[Title/Abstract] OR oxycontin cr[Title/Abstract] OR oxycodne[Title/Abstract] OR oxycontin cr[Title/Abstract] OR oxyidse[Title/Abstract] OR oxycontin cr[Title/Abstract] OR oxyidse[Title/Abstract] OR oxycontin cr[Title/Abstract] OR oxyidse[Title/Abstract] OR oxycon[Title/Abstract] OR oxy	75234
<u>#4</u>	Add	Search "Oxycodone"[Mesh]	<u>1774</u>

#1	MeSH descriptor: [Oxycodone] explode all trees	\bigcirc	<u>484</u>
#2	Dihydrone:ti,ab,kw or Dinarkon:ti,ab,kw or Oxycone:ti,ab,kw or Dihydrohydroxycodeinone:ti,ab,kw or Oxycodeinon:ti,ab,kw or Oxiconum:ti,ab,kw or Theocodin:ti,ab,kw or Oxycontin:ti,ab,kw or Oxycodone:ti,ab,kw or Pancodine:ti,ab,kw or Eucodal:ti,ab,kw or dihydrohydroxydodeinone:ti,ab,kw or dihydrone:ti,ab,kw or dinarkon:ti,ab,kw or endone:ti,ab,kw or eubine:ti,ab,kw or eucodal:ti,ab,kw or eucodale:ti,ab,kw or endone:ti,ab,kw or eubine:ti,ab,kw or eucodal:ti,ab,kw or eucodale:ti,ab,kw or eucodalum:ti,ab,kw or eudoamine:ti,ab,kw or eutodal:ti,ab,kw or eukodal:ti,ab,kw or eucodalum:ti,ab,kw or eurodamine:ti,ab,kw or eutagen:ti,ab,kw or hydrocodal:ti,ab,kw or narcobasina:ti,ab,kw or ludonal:ti,ab,kw or m-oxy:ti,ab,kw or medicodal:ti,ab,kw or narcobasina:ti,ab,kw or narcobasine:ti,ab,kw or narcosin:ti,ab,kw or nargenol:ti,ab,kw or oxicone:ti,ab,kw or oxanest:ti,ab,kw or oxaydo:ti,ab,kw or oyton:ti,ab,kw or oxicone:ti,ab,kw or oxicontin:ti,ab,kw or oxiconum:ti,ab,kw or oxxicon:ti,ab,kw or oxy in:ti,ab,kw or oxycod:ti,ab,kw or oxycodeinonhydrochloride:ti,ab,kw or oxycodonhydrochlorid:ti,ab,kw or oxycodyl:ti,ab,kw or oxycodeinonhydrochloride:ti,ab,kw or oxycontin:ti,ab,kw or oxygesic:ti,ab,kw or oxycontin lp:ti,ab,kw or oxydose:ti,ab,kw or oxycontin:ti,ab,kw or oxycontin cr:ti,ab,kw or percolone:ti,ab,kw or oxydose:ti,ab,kw or oxyfast:ti,ab,kw or pavinal:ti,ab,kw or percolone:ti,ab,kw or ponarcin:ti,ab,kw or stupenal:ti,ab,kw or supeudol:ti,ab,kw or tebodal:ti,ab,kw or sinthiodal:ti,ab,kw or stupenal:ti,ab,kw or xtampa:ti,ab,kw or tampza:ti,ab,kw or xtampza:ti,ab,kw or thecodin:ti,ab,kw or xtampa:ti,ab,kw or tampza:ti,ab,kw or tampza:ti,ab,kw or thecodin:ti,ab,kw or stampa:ti,ab,kw or tampza:ti,ab,kw or tampza:ti,ab,kw		1301
#3	MeSH descriptor: [Laparoscopy] explode all trees	\bigcirc	<u>6120</u>
#4	MeSH descriptor: [Cholecystectomy, Laparoscopic] explode all trees	m	<u>1325</u>
#5	MeSH descriptor: [Hand-Assisted Laparoscopy] explode all trees	m	<u>18</u>
#6	Laparoscopy:ti,ab,kw or Laparoscopies:ti,ab,kw or Celioscopy:ti,ab,kw or Celioscopies:ti,ab,kw or Peritoneoscopy:ti,ab,kw or Peritoneoscopies:ti,ab,kw or "Laparoscopic Surgical Procedures":ti,ab,kw or "Laparoscopic Surgical Procedure":ti,ab,kw or "Laparoscopic Surgery:ti,ab,kw OR " Laparoscopic Surgeries:ti,ab,kw or "Laparoscopic Assisted Surgery:ti,ab,kw OR " Laparoscopic Assisted Surgeries:ti,ab,kw or videolaparoscopy:ti,ab,kw or videolaparoscopies:ti,ab,kw	TH	6678
#7	#1 or #2	141	<u>1301</u>
#8	#3 or #4 or #5 or #6	141	7861
#9	#7 and #8	141	<u>50</u>

The Cochrane Library

All Results (50)	Cochrane Central Register of Controlled Trials : Issue 7 of 12, July 2017							
Cochrane Reviews (0)	There are	50 results from 1068354 record	ds for your search on #9 - #	7 and #8 in Trials in the	e strategy currently being	edited		
All	Pages 1	25 26 - 50		Sort by	Relevance: high to low	-		
Review								
Protocol	Select all	Export all Export selecte	d					
Other Reviews (0)		Comparison of N2O and CO2 n	aoumonoritonoume during la	parascanic chalacystacto	amy with enacial reference	to		
Trials (50)		Comparison of N2O and CO2 pneumoperitoneums during laparoscopic cholecystectomy with special reference to postoperative pain						
Methods Studies (0)		Aitola P , Airo I , Kaukinen S and						
Technology Assessments (0)		Surgical laparoscopy & endosco Online Publication Date: 2012	opy, 1998, 8(2), 140					
Economic Evaluations (0)								
Cochrane Groups (0)								
All		A Comparison of Oxycodone an Decremental Infusion after Lapa		tient-Controlled Analgesi:	a with a Time-Scheduled			
Current Issue		Kwon YS , Jang JS , Lee NR , Ki Pain research & manadement :	m SY					

Received: 28 March 2020 Accepted: 20 November 2020 Published online: 09 January 2021

References

- Bajwa SJ, Kulshrestha A. Anaesthesia for laparoscopic surgery: general vs regional anaesthesia. J Minim Access Surg. 2016;12:4–9.
- Chestnut DH. Efficacy and safety of epidural opioids for postoperative analgesia. Anesthesiology. 2005;102:221–3.
- Choi EK, Kwon N, Park SJ. Comparison of the effects of oxycodone versus fentanyl on airway reflex to tracheal extubation and postoperative pain during anesthesia recovery after laparoscopic cholecystectomy: a double-blind, randomized clinical consort study. Medicine (Baltimore). 2018;97(13):e0156.
- Choi YJ, Park SW, Kwon HJ, Choi JM, Lee YM. Efficacy of early intravenous bolus oxycodone or fentanyl in emergence from general anaesthesia and postoperative analgesia following laparoscopic cholecystectomy: a randomized trial. J Int Med Res. 2015;43:809–18.
- Golubovic S, Golubovic V, Cindric-Stancin M, Tokmadzic VS. Intraperitoneal analgesia for laparoscopic cholecystectomy: bupivacaine versus bupivacaine with tramadol. Collegium Antropologicum. 2009;33:299–302.
- Golzari SE, Nader ND, Mahmoodpoor A. Underlying mechanisms of postoperative pain after laparoscopic surgery. JAMA Surg. 2016;151:295–6.
- Han L, Su Y, Xiong H, Niu X, Dang S, Du K, et al. Oxycodone versus sufentanil in adult patient-controlled intravenous analgesia after abdominal surgery: a prospective, randomized, double-blinded, multiple-center clinical trial. Medicine (Baltimore). 2018;97:e11552.
- Higgins JPT, Green S.Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org. Accessed Mar 2011
- Hwang BY, Kwon JY, Kim E, Lee DW, Kim TK, Kim HK. Oxycodone vs. fentanyl patient-controlled analgesia after laparoscopic cholecystectomy. Int J Med Sci. 2014;11:658–62.
- Jin HS, Shin JY, Kim YC, Lee SC, Choi EJ, Lee PB, et al. Predictive factors associated with success and failure for radiofrequency thermocoagulation in patients with trigeminal neuralgia. Pain Physician. 2015;18:537–45.
- Kim MK, Ahn SE, Shin E, Park SW, Choi JH, Kang HY. Comparison of analgesic efficacy of oxycodone and fentanyl after total hip replacement surgery: a randomized controlled trial. Medicine (Baltimore). 2018;97:e13385.
- 12. Kim NS, Lee JS, Park SY, Ryu A, Chun HR, Chung HS, et al. Oxycodone versus fentanyl for intravenous patient-controlled analgesia after laparoscopic supracervical hysterectomy: a prospective, randomized, doubleblind study. Medicine (Baltimore). 2017;96:e6286.
- Koch S, Ahlburg P, Spangsberg N, Brock B, Tonnesen E, Nikolajsen L. Oxycodone vs. fentanyl in the treatment of early post-operative pain after laparoscopic cholecystectomy: a randomised double-blind study. Acta Anaesthesiol Scand. 2008;52:845–50.

- Kwon YS, Jang JS, Lee NR, et al. A comparison of oxycodone and alfentanil in intravenous patient-controlled analgesia with a time-scheduled decremental infusion after laparoscopic cholecystectomy. Pain Res Manag. 2016;2016:7868152.
- Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE, Raeder J. A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. Anesth Analg. 2009;109:1279–83.
- Liguori S, Gottardi M, Micheletto G, Bruno L. Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study. Eur Rev Med Pharmacol Sci. 2010;14:185–90.
- Liu LL, Gropper MA. Postoperative analgesia and sedation in the adult intensive care unit: a guide to drug selection. Drugs. 2003;63:755–67.
- Olesen AE, Staahl C, Arendt-Nielsen L, Drewes AM. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. Br J Clin Pharmacol. 2010;70:189–200.
- Ortiz-Gomez JR, Pereperez-Candel M, Vazquez-Torres JM, Rodriguez-Del Rio JM, Torron-Abad B, Fornet-Ruiz I, et al. Postoperative analgesia for elective total knee arthroplasty under subarachnoid anesthesia with opioids: comparison between epidural, femoral block and adductor canal block techniques (with and without perineural adjuvants). A prospective, randomized, clinical trial. Minerva Anestesiol. 2017;83:50–8.
- Park JH, Lee C, Shin Y, An JH, Ban JS, Lee JH. Comparison of oxycodone and fentanyl for postoperative patient-controlled analgesia after laparoscopic gynecological surgery. Korean J Anesthesiol. 2015;68:153–8.
- Peng K, Liu HY, Wu SR, Cheng H, Ji FH. Effects of combining dexmedetomidine and opioids for postoperative intravenous patientcontrolled analgesia: a systematic review and meta-analysis. Clin J Pain. 2015;31:1097–104.
- Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain. 1997;73:151–7.
- 23. Ruan X, Mancuso KF, Kaye AD. Revisiting oxycodone analgesia: a review and hypothesis. Anesthesiol Clin. 2017;35:e163–74.
- Schulman J. Systematic reviews and meta-analysis: why might more clinical trials yield no greater precision? J Perinatol. 2017;37:1169–70.
- Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM. A comparative study of oxycodone and morphine in a multi-modal, tissuedifferentiated experimental pain model. Pain. 2006;123:28–36.
- Staahl C, Upton R, Foster DJ, Christrup LL, Kristensen K, Hansen SH, et al. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol. 2008;48:619–31.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.